Clinical Trials Logo
  1. Home
  2. Immune-related Adverse Event
  3. NCT06037811

Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis

Inflammatory Arthritis Clinical Trial

Official title:
Early Adalimumab Induction for Treatment of Steroid Dependent Immune Checkpoint Inhibitor Associated Inflammatory Arthritis: A Pragmatic Randomized Clinical Trial

Clinical Trial Summary

This study will examine the effectiveness of administering adalimumab as a treatment for patients in the early stages of steroid-dependent immune checkpoint Inhibitor associated inflammatory arthritis (ir-IA). Adalimumab (ADA) is a TNF inhibitor (TNFi) that is well established as a standard of care treatment for numerous types of inflammatory arthritis. It is hoped that adalimumab at the early stages of the ir-IA will reduce the symptoms and therefore reduce the need for steroids. This study is a pragmatic randomized clinical trial. Patients will be randomized 1:1 to each treatment group. To evaluate the steroid sparing effect of early induction six doses of Adalimumab will be administered to patients in the study treatment arm as compared to the usual standard of care of a predefined corticosteroid regimen and taper at 12 weeks administered in the control group.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06037811
Study type Interventional
Source Lawson Health Research Institute
Contact Tom Appleton, MD, PhD, FRCPC
Phone 519-646-6100
Email tom.appelton@sjhc.london.on.ca
Status Not yet recruiting
Phase Phase 2
Start date April 2024
Completion date November 2025
View Details
See also
  Status Clinical Trial Phase
Terminated NCT04249817 - Keeping Stable Inflammatory Arthritis Patients in Their Communities With the Advanced Clinician Practitioner in Arthritis Care N/A
Not yet recruiting NCT06162195 - The ACTIVE Trial: A Prospective Randomised Control Trial Of The H1 Implant Versus Total Hip Replacement N/A
Completed NCT01303874 - Etanercept and Methotrexate in Patients to Induce Remission in Early Arthritis (EMPIRE) Phase 4
Active, not recruiting NCT03343171 - Continuum Ceramic on Ceramic Bearing Post Market Clinical Follow-Up Study
Recruiting NCT04426747 - Impact of Barriers and Facilitators to Physical Activity in Patients With Inflammatory Arthritis
Active, not recruiting NCT04956380 - Self-assessment Triage in Inflammatory Arthritis N/A
Active, not recruiting NCT02538757 - Safety and Effectiveness Study of the Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE) Phase 2
Completed NCT01874067 - C-GLOVES: the Effectiveness of Compression Gloves in Arthritis
Completed NCT03140995 - Sleep and Exercise in Rheumatoid Arthritis N/A
Withdrawn NCT02027298 - Abatacept for Patients With Inflammatory Arthritis Associated With Sjögren's Syndrome: an Open-Label Phase II Study Phase 2
Recruiting NCT00512239 - Prognostic Evaluation of Inflammatory Polyarthritis of Recent Onset
Terminated NCT03937856 - Smartphone Mindfulness Meditation for Patients With Rheumatic Diseases N/A
Completed NCT02436785 - Do Inflammatory Arthritis Inpatients Receiving Group Music Therapy Improve Pain Compared to Music Listening? N/A
Completed NCT02538341 - Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial) Phase 2
Completed NCT02465879 - Allied Health in Rheumatology Triage Project N/A
Completed NCT03672916 - Allofit® IT Ceramic Bearing System in Total Hip Arthroplasty
Completed NCT04806867 - Selection of Patients With Chronic Inflammatory Rheumatism Requiring Management During the COVID-19 Pandemia
Active, not recruiting NCT01307384 - Zimmer Continuum Metal on Polyethylene (MoP) PostMarket Clinical Followup (PMCF) Study
Terminated NCT03672370 - PMCF Study on the Safety and Performance of the Alloclassic Variall Cup Ceramic Bearing System in Total Hip Arthroplasty
Not yet recruiting NCT05216757 - Efficacy and Safety of Iguratimod in Patients With Hand Osteoarthritis (ESIGO) Phase 2/Phase 3